Anticoagulation for venous thromboembolism: What if they bleed?

Hamostaseologie

Volumn 32, Issue 1, 2012, Pages 40-44

  Palareti, G ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anticoagulation; Bleeding; Haemorrhages; VTE

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; FRESH FROZEN PLASMA; HEPARIN; HEPARIN DERIVATIVE; PHENPROCOUMON; PROTHROMBIN COMPLEX; WARFARIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL DECISION MAKING; DRUG HALF LIFE; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; REVIEW; RISK FACTOR; THAWING; THROMBOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84861518765     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.5482/ha-1180     Document Type: Review

References (30)

1. Palareti G, Cosmi B. Predicting the risk of recurrence of venous thromboembolism. Curr Opin Hematol 2004; 11: 192-197.
2. Kahn SR. Natural history of postthrombotic disease: Transition from acute to chronic disease. J Vasc Surg 2010; 52: 62S-64S.
3. th ed). Chest 2008; 133: 454S-545S.
4. Kearon C. Indefinite anticoagulation after a first episode of unprovoked venous thromboembolism: yes. J Thromb Haemost 2007; 5: 2330-2335.
5. Baglin T. Unprovoked deep vein thrombosis should be treated with long-term anticoagulation-no. J Thromb Haemost 2007; 5: 2336-2339.
6. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
7. Briz M, Talks K, Hanley J et al. Reversal of warfarininduced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study. J Thromb Haemost 2010; 8: 1123-1125.
8. Makris M, Greaves M, Phillips WS et al. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77: 477-480.
9. th edition). Chest 2008; 133: 160S-198S.
10. Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost 2006; 4: 1853-1863.
11. Ozgonenel B, Omalley B, Krishen P, Eisenbrey AB. Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol 2007; 82: 1091-1094.
12. Lee SB, Manno EM, Layton KF, Wijdicks EFM. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006; 67: 1272-1274.
13. Lankiewicz MW, Hays J, Friedman KD et al. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-970.
14. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008; 83: 137-143.
15. rd ed-2005 update. Br J Haematol 2006; 132: 277-285.
16. Pabinger I, Brenner B, Kalina U et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008; 6: 622-631.
17. Holland L, Warkentin TE, Refaai M et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due towarfarin overdose. Transfusion (Paris) 2009; 49: 1171-1177.
18. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999; 45: 1113-1118.
19. Hull R, Delmore T, Genton E et al. Warfarin sodium versus low dose heparin in the long term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
20. Nielsen HK, Husted SE, Krusell LR et al. Anticoagulant therapy in deep venous thrombosis-a randomized controlled study. Thromb Res 1994; 73: 215-226.
21. Kearon C, Hirsh J. Current concepts: management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506-1511.
22. Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107: I22-I30.
23. rd. Recurrence of venous thromboembolism. Surgery 1973; 73: 823-827.
24. Eichinger S, Weltermann A, Minar E et al. Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism. Arch Intern Med 2004; 164: 92-96.
25. Imberti D, Prisco D. Retrievable vena cava filters: key considerations. Thromb Res 2008; 122: 442-449.
26. Segal JB, Streiff MB, Hoffman LV et al. Management of venous thromboembolism: A systematic review for a practice guideline. Ann Intern Med 2007; 146: 211-222.
27. Ageno W, Garcia D, Aguilar MI et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol 2009; 84: 584-588.
28. Hui AJ, Wong RM, Ching JY et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004; 59: 44-48.
29. Garcia DA, Regan S, Henault LE et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168: 63-69.
30. Clark NP, Witt DM, Delate T et al. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: The Low INR Study. Pharmacotherapy 2008; 28: 960-967